The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.
The innovative HPAPIs segment to dominate the market in 2018
Based on type, the HPAPIs market is segmented into innovative and generic HPAPIs. In 2018, the innovative HPAPIs segment is expected to account for the largest share of the market. The large share can be attributed to the increased investments of innovator companies in R&D, manufacture, marketing, and supply of innovative HPAPIs as the revenue generated from these molecules are considerably high.
Download PDF Brochure@
The objectives of this study are as follows:
# To define, describe, and forecast the global HPAPI market on the basis of type, type of manufacturer, type of synthesis, therapeutic application, and region
# To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
# To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market|
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
# To forecast the size of the market segments of North America, Europe, Asia, and the Rest of the World (RoW)
# To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
# To track and analyze competitive developments such as agreements, partnerships, collaborations, and alliances; mergers and acquisitions; expansions; and R&D activities in the global market
Based on type of manufacturer, the captive manufacturers segment to dominate the market in 2018
On the basis of type of manufacturer, the HPAPIs market is segmented into captive HPAPI and merchant HPAPI manufacturers. In 2018, the captive HPAPI manufacturers segment is expected to account for the largest share of the market. The large share of this segment is attributed to the preference of innovative companies to maintain in-house manufacturing facilities for economic benefits.
The biotech HPAPIs segment is projected to grow at the highest CAGR during the forecast period.
On the basis of type of synthesis, the HPAPIs market is categorized into synthetic and biotech HPAPIs. The biotech HPAPIs segment is expected to grow at the highest CAGR during the forecast period. Advances in biotechnology, growing demand for antibody-drug conjugates, growing demand due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies are the major factors driving the growth of this market.
Target Audience for this Report:
# Manufacturers of HPAPI
# Distributors and suppliers of HPAPIs
# Potential investors in the HPAPI market
# Pharmaceutical companies
# Biotechnology companies
# Contract manufacturing organizations
# Life science research centers
# Healthcare payers
Request Sample Pages@
North America to dominate the HPAPIs market in 2018
In 2018, North America is expected to account for the largest share of the market followed by Europe. Factors such growing incidence of cancer, increasing investments in cancer research, technological advancements in HPAPI manufacturing, growing CMOs market, constructive government reforms like the Patient Protection and Affordable Care Act, growing focus of leading pharmaceutical companies in the HPAPIs segment, and increasing demand for antibody-drug conjugates (ADCs) are responsible for the large share of North America in the global HPAPIs market.
The HPAPIs market is fragmented, with the presence of several large as well as emerging players. Prominent players in the HPAPIs market include Pfizer (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva (Israel), Eli Lilly and Company (US), Merck (US), AbbVie (US), Mylan (US), and F. Hoffmann-La Roche (Switzerland). Players in this market are adopting various organic and inorganic strategies, such as agreements, collaborations, alliances, and partnerships; mergers and acquisitions; and expansions.
No comments:
Post a Comment